Who is sponsoring NCT04531657?

NCT04531657 is sponsored by University of Wisconsin, Madison.

What drugs are being tested in NCT04531657?

Interventions: Influenza vaccine.

What is the status of NCT04531657?

NCT04531657 is currently COMPLETED.

Last reviewed 2020-10-20 · How we verify

Influenza Vaccine Antibody Response and 6-month Persistence in Lung Transplant Recipients Using Two Definitions of Seroprotection

NCT04531657 COMPLETED

This a sub-study of a 5-year study designed to investigate how antibody and T cell responses following influenza vaccine compare among lung transplant patients, patients waiting for lung transplantation, and healthy individuals. This study is designed to investigate two different definitions of influenza vaccine seroprotection at mid-season in lung transplant patients.

Details

Lead sponsor	University of Wisconsin, Madison
Status	COMPLETED
Enrolment	79
Start date	2004-12
Completion	2009-07

Conditions

Influenza

Interventions

Influenza vaccine

Primary outcomes

Number of Participants with Seroprotection to Influenza Vaccine: 40 HAU — up to 6 months
The hypothesis is that seroprotection, defined as 40 HAU or greater, will persist up to 6 months at high rates in lung transplant patients and that these rates will be comparable to the rates in healthy individuals. Seroprotection (antibody titer greater than or equal to 1:40) will be reported for H1N1, H3N2, and B viral antigens.

Countries

United States